COVID-19 Primary Care Platform for Early Treatment and Recovery (COPPER) Study

Summary

The COVID-19 coronavirus has led to a global pandemic of respiratory diseases with an increase in hospitalization and death risk. To keep COVID-19 manageable for healthcare, early treatment is urgently needed to avoid hospitalization. Dexamethasone can dampen the exaggerated cytokine response to COVID-19 and is a promising agent for preventing disease aggravation, hospitalization and death. However, the evidence on the effectiveness, safety and cost-effectiveness of dexamethasone treatment in primary care is inconclusive.

Timeline

Start

2021-02-16

Primary completion

2021-04-23

Completion

2021-04-23

Outcome

Outcome not reported

Stopped: “Too few patients”

Drugs

Indications